Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations at the American Heart Association Scientific Sessions 2024 taking place in Chicago, IL from November 16, 2024 - November 18, 2024.

Aficamten

Title: Modifiability of Post-Exercise Oxygen Uptake Recovery Patterns: A Substudy of the SEQUOIA-HCM Trial
Presenter: Gregory D. Lewis, M.D., Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing Laboratory, Professor of Medicine, Harvard Medical School
Date: November 17, 2024
Session Title: Advances in Identification and Management of Hypertrophic Cardiomyopathy
Session Time: 9:30 AM – 10:55 AM CT
Presentation Time: 10:00 AM – 10:05 AM CT
Location: Zone 2‚ Moderated Digital Poster 9

Title: Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: November 17, 2024
Session Title: Cardiomyopathy Mayhem
Session Time: 3:15 PM – 4:20 PM CT
Presentation Time: 4:05 PM – 4:10 PM CT
Location: Zone 2‚ Moderated Digital Poster 5

Title: Changes in EQ-5D-5L with Aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM): the SEQUOIA-HCM Trial
Presenter: P. Christian Schulze, MD, PhD, Professor of Medicine, Chair, Department of Internal Medicine, Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, University Hospital Jena, Jena, Germany
Date: November 18, 2024
Session Title: Cardiomyopathy Potpourri 2
Session Time: 1:30 PM – 2:30 PM CT
Location: Zone 2      

Omecamtiv Mecarbil

Title: Effect of the Cardiac Myosin Activator Omecamtiv Mecarbil on Risk of Ventricular Arrhythmias in Heart Failure with Reduced Ejection Fraction: the GALACTIC-HF Trial
Presenter: Alberto Foà, M.D., Ph.D., Cardiologist, Brigham and Women's Hospital, Harvard Medical School, Boston
Date: November 16, 2024
Session Title: Bulking Up: The Latest in Hypertrophic Cardiomyopathy
Session Time: 2:50 PM – 4:05 PM CT
Presentation Time: 2:50 PM – 2:55 PM CT
Location: Zone 1‚ Moderated Digital Poster 4

Title: Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Age: the GALACTIC-HF Trial
Presenter: Henri Lu, M.D., Clinical Research Fellow, Heart Failure, Harvard University
Date: November 18, 2024
Session Title: Taking Action to Understand the Ejection Fraction
Session Time: 10:30 AM – 11:30 AM CT
Location: Zone 2

Health Economics and Outcomes Research

Title: Association of Sociodemographic Characteristics on Costs of Care in Patients with Obstructive Hypertrophic Cardiomyopathy
Presenter: Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of Pennsylvania
Date: November 17, 2024
Session Title: Socioeconomic Insights and Innovations in Heart Failure
Session Time: 9:30 AM – 10:55 AM CT
Presentation Time: 9:50 AM – 9:55 AM CT
Location: Zone 2‚ Moderated Digital Poster 5

About Cytokinetics

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), Cytokinetics submitted an NDA for aficamten to the U.S. Food & Drug Administration and is progressing regulatory submissions for aficamten for the treatment of obstructive HCM in Europe. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of heart failure with preserved ejection fraction (HFpEF).

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757